Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with David M. O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at the Ohio State University (OSU) College of Medicine, as well as the director of the Division of Gynecologic Oncology, director of Clinical Research in Gynecologic Oncology, and co-director of the Gynecologic Oncology Phase I Program at The OSU Comprehensive Cancer Center–James, to discuss key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
In our exclusive interview, O’Malley discussed the key takeaways from several trials that were presented during the the 2021 SGO Annual Meeting on Women’s Cancer, including the phase 3 KEYNOTE-775 (NCT03517449) and SORAYA (NCT04296890) trials, the phase 2 NRG-GY012 trial, and more!